GenMark Diagnostics (NASDAQ:GNMK) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.

Other equities analysts have also issued reports about the stock. Zacks Investment Research upgraded shares of GenMark Diagnostics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 29th. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price objective on shares of GenMark Diagnostics in a research report on Friday, January 19th. BTIG Research set a $11.00 price objective on shares of GenMark Diagnostics and gave the company a “buy” rating in a research report on Tuesday, January 16th. Finally, Canaccord Genuity lowered their price objective on shares of GenMark Diagnostics from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, February 28th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $10.60.

How to Become a New Pot Stock Millionaire

Shares of GenMark Diagnostics (NASDAQ GNMK) traded down $0.15 on Wednesday, hitting $5.33. 71,362 shares of the stock were exchanged, compared to its average volume of 476,345. The company has a current ratio of 3.44, a quick ratio of 3.04 and a debt-to-equity ratio of 0.29. The stock has a market capitalization of $284.11, a price-to-earnings ratio of -4.40 and a beta of 0.99. GenMark Diagnostics has a twelve month low of $3.63 and a twelve month high of $13.67.

GenMark Diagnostics (NASDAQ:GNMK) last announced its earnings results on Tuesday, February 27th. The medical equipment provider reported ($0.26) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.26). The business had revenue of $16.02 million for the quarter, compared to analyst estimates of $15.82 million. GenMark Diagnostics had a negative net margin of 117.77% and a negative return on equity of 91.14%. analysts expect that GenMark Diagnostics will post -0.78 earnings per share for the current fiscal year.

In related news, insider Hany Massarany sold 6,584 shares of GenMark Diagnostics stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $4.37, for a total value of $28,772.08. Following the transaction, the insider now directly owns 357,190 shares in the company, valued at approximately $1,560,920.30. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Michael Kagnoff acquired 10,000 shares of the stock in a transaction that occurred on Thursday, March 1st. The stock was purchased at an average price of $4.22 per share, for a total transaction of $42,200.00. Following the completion of the transaction, the director now owns 74,413 shares in the company, valued at $314,022.86. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 50,164 shares of company stock worth $217,957. 7.50% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the business. Wrapmanager Inc. boosted its position in shares of GenMark Diagnostics by 121.3% during the 4th quarter. Wrapmanager Inc. now owns 39,547 shares of the medical equipment provider’s stock worth $165,000 after purchasing an additional 21,679 shares in the last quarter. UBS Asset Management Americas Inc. boosted its position in shares of GenMark Diagnostics by 111.1% during the 4th quarter. UBS Asset Management Americas Inc. now owns 49,400 shares of the medical equipment provider’s stock worth $206,000 after purchasing an additional 26,000 shares in the last quarter. OLD National Bancorp IN boosted its position in shares of GenMark Diagnostics by 120.6% during the 4th quarter. OLD National Bancorp IN now owns 49,765 shares of the medical equipment provider’s stock worth $208,000 after purchasing an additional 27,208 shares in the last quarter. Fairpointe Capital LLC purchased a new stake in shares of GenMark Diagnostics during the 4th quarter worth $220,000. Finally, FDx Advisors Inc. boosted its position in shares of GenMark Diagnostics by 124.1% during the 4th quarter. FDx Advisors Inc. now owns 53,689 shares of the medical equipment provider’s stock worth $224,000 after purchasing an additional 29,729 shares in the last quarter.

COPYRIGHT VIOLATION WARNING: “GenMark Diagnostics (GNMK) Raised to “Hold” at BidaskClub” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.dailypolitical.com/2018/03/14/genmark-diagnostics-gnmk-raised-to-hold-at-bidaskclub.html.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

Analyst Recommendations for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.